Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Li, Liuzhea | Wang, Xiao-Hongb | Banerjee, Sagarikaa | Volsky, Barbaraa | Williams, Constancea | Moody, M. Anthonyc | Zolla-Pazner, Susana; b | Gorny, Miroslaw K.a; *
Affiliations: [a] Department of Pathology, New York University School of Medicine, New York, NY, USA | [b] Veterans Affairs New York Harbor Healthcare System, New York, NY, USA | [c] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
Correspondence: [*] Corresponding author: Miroslaw K. Gorny, 423 East 23rd Street, Room 18124N, New York, NY 10010, USA. Tel.: +1 212 263 4156; Fax: +1 212 951 6321; E-mail: mirek.gorny@nyumc.org
Abstract: The production of human monoclonal antibodies (mAbs) has been improved recently using the single B cell and PCR technology. A number of new anti-HIV-1 mAbs directed to various epitopes were produced by selecting single B cells from HIV positive individuals using the HIV-1 envelope (Env) proteins, and we tested whether the peptide can select B cells specific to a particular Env epitope. Using the fluorescently-labeled peptide tetramer representative of the V3 loop of HIV-1 Env gp120 for staining the B cells derived from one HIV-1 infected donor, four clonal human mAbs were produced with specificity to the V3 region. The clonality of the four V3 mAbs was based on the usage of the same immunoglobulin genes and almost identical sequence of CDRs. The amino acid changes were present only in the framework and, possibly, they could be related to the differences observed in the relative affinity binding of these four mAbs to V3 antigen. One representative V3 mAb displayed very potent neutralizing activity to one of two viruses tested. This study shows the feasibility of utilizing a peptide tetramer to select epitope-specific B cells and produce mAbs.
Keywords: HIV-1, V3 region, immunoglobulin gene usage, human monoclonal antibodies, HIV neutralizing antibodies
DOI: 10.3233/HAB-130264
Journal: Human Antibodies, vol. 21, no. 3-4, pp. 65-73, 2012
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl